Trials / Completed
CompletedNCT00417170
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
A Double-blind, Double Dummy, Randomized Parallel Design Trial to Study the Effects of 12 Weeks of Treatment With 300mg Aliskiren vs. 5mg Amlodipine on Insulin Resistance and Endothelial Dysfunction in Hypertensive Patients With Metabolic Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome. The efficacy of Aliskiren was compared to Amlodipine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | Aliskiren 300 mg tablets taken orally once daily |
| DRUG | Amlodipine | Amlodipine 5 mg capsule taken orally once daily |
| DRUG | Placebo Aliskiren | Placebo Aliskiren taken orally once daily. |
| DRUG | Placebo Amlodipine | Placebo Amlodipine taken orally once daily |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2006-12-29
- Last updated
- 2011-09-26
- Results posted
- 2011-08-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00417170. Inclusion in this directory is not an endorsement.